EUVIMEDEUVIMED entdecken
Crossref

Bimekizumab efficacy though 144 weeks in moderate to severe plaque psoriasis: results documented patients from the BE RADIANT study

Miloslav Salavec

Dermatologie pro praxi · 07.10.2024 · 18 (3) · 135-139

DOI: 10.36290/der.2024.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologie pro praxi, erschienen am 07.10.2024. Verfasst von Miloslav Salavec. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Salavec, M. (2024). Bimekizumab efficacy though 144 weeks in moderate to severe plaque psoriasis: results documented patients from the BE RADIANT study. Dermatologie pro praxi, 18(3), 135-139. https://doi.org/10.36290/der.2024.027

Vancouver

Salavec M. Bimekizumab efficacy though 144 weeks in moderate to severe plaque psoriasis: results documented patients from the BE RADIANT study. Dermatologie pro praxi. 2024;18(3):135-139. doi:10.36290/der.2024.027

BibTeX
@article{Salavec2024,
  author = {Salavec, Miloslav},
  title = {Bimekizumab efficacy though 144 weeks in moderate to severe plaque psoriasis: results documented patients from the BE RADIANT study},
  journal = {Dermatologie pro praxi},
  year = {2024},
  volume = {18},
  number = {3},
  pages = {135--139},
  doi = {10.36290/der.2024.027}
}
Kostenlos starten →